Dae Gon Ha
Stock Analyst at Stifel
(2.69)
# 2,126
Out of 4,996 analysts
46
Total ratings
39.47%
Success rate
8.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Reinstates: Buy | $89 | $72.76 | +22.32% | 4 | Aug 11, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.44 | +267.65% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $3.24 | -7.41% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $64.96 | +13.92% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $8.84 | -66.06% | 4 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $16.31 | +292.40% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $167.82 | +31.09% | 4 | Sep 11, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $29.08 | +336.73% | 2 | May 31, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Buy | $48 | $3.26 | +1,372.39% | 4 | Sep 13, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $18 | $5.12 | +251.56% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $1.50 | +366.67% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $99.16 | -74.79% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $8.24 | +94.17% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $11.56 | +2,365.40% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.11 | +847.87% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.11 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $22.39 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $7.63 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.30 | +823.08% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $9.16 | +5,249.34% | 2 | Oct 23, 2017 |
Mirum Pharmaceuticals
Aug 11, 2025
Reinstates: Buy
Price Target: $89
Current: $72.76
Upside: +22.32%
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.44
Upside: +267.65%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $3.24
Upside: -7.41%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $64.96
Upside: +13.92%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $8.84
Upside: -66.06%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $16.31
Upside: +292.40%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $167.82
Upside: +31.09%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $29.08
Upside: +336.73%
Rocket Pharmaceuticals
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $3.26
Upside: +1,372.39%
Prime Medicine
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $5.12
Upside: +251.56%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $1.50
Upside: +366.67%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $99.16
Upside: -74.79%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $8.24
Upside: +94.17%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $11.56
Upside: +2,365.40%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $2.11
Upside: +847.87%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $12.11
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $22.39
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $7.63
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.30
Upside: +823.08%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $9.16
Upside: +5,249.34%